CHE
Chemed Corporation · Healthcare · Medical - Care Facilities
Momentum-inputs (vergelijkbare managers):
breedte van houders -4.3% ·
aandelenstroom -2.7% ·
netto nieuwe posities -9.1%
· formule
Brede distributie: dalende aandelen en minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 53.78K | $26.72M | +1 | −1 |
| Q2 2026 | 131 | +6 | 8.89M | $4.13B | +9 | −4 |
| Q1 2026 | 129 | 0 | 8.71M | $3.29B | +5 | −6 |
| Q4 2025 | 129 | -2 | 9.90M | $4.23B | +1 | −2 |
| Q3 2025 | 22 | -1 | 5.87M | $2.63B | n/a | −2 |
| Q2 2025 | 21 | +1 | 4.75M | $2.31B | +2 | −1 |
| Q1 2025 | 17 | 0 | 1.55M | $954.33M | +1 | −1 |
| Q4 2024 | 17 | +1 | 1.54M | $817.61M | +2 | −1 |
| Q3 2024 | 15 | 0 | 874.91K | $525.85M | n/a | n/a |
| Q2 2024 | 15 | n/a | 976.21K | $529.86M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 1.54M | -4.0% | $688.84M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passief) | 1.34M | -0.1% | $598.74M | 0.0% | ▼ Trim | 2 | SEC ↗ ×18 |
| 3 | JPMorgan Chase ✦ | 999.94K | n/a | $447.71M | 0.0% | n/c | 1 | SEC ↗ ×24 |
| 4 | State Street Global Advisors ✦ (passief) | 472.11K | -1.0% | $211.38M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passief) | 366.56K | +3.0% | $164.14M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Morgan Stanley ✦ | 349.26K | n/a | $156.38M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 7 | AQR Capital Management ✦ | 172.11K | -14.4% | $77.06M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 8 | Goldman Sachs Group ✦ | 115.05K | n/a | $51.51M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Arrowstreet Capital ✦ | 95.57K | +740.9% | $42.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 85.81K | -54.5% | $38.42M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 11 | Millennium Management ✦ | 79.53K | -41.0% | $35.61M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 61.13K | +265.3% | $27.37M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 13 | Renaissance Technologies ✦ | 49.00K | -44.6% | $21.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 42.74K | +319.1% | $19.14M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 23.93K | -40.4% | $10.71M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 16 | GAMCO Investors ✦ | 20.45K | +0.8% | $9.16M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 15.98K | -55.6% | $7.15M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | Marshall Wace ✦ | 14.15K | +1089.0% | $6.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 10.90K | -48.7% | $4.88M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 9.76K | -0.1% | $4.37M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 4.53K | +59.5% | $2.03M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 22 | Adage Capital Partners ✦ | 2.50K | -44.4% | $1.12M | 0.0% | ▼ Trim | 2 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Norges Bank | $89.39M | was 0.0% |
| Wellington Management | $957,791 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 486 houders, 12.67M aandelen, $4.47B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 2.00K aand · $1.03M
Officer, Director · 2.00K aand · $1.00M
Officer, Director · 2.00K aand · $1.08M
Officer · 1.00K aand · $541,040
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie